Replies to post #110046 on Savvy Trades and Investments

[bbotcs]

r59: BHVN
This neuroscience pharma company is mind-blowing, no pun intended. They developed a blockbuster drug, Nurtec?, that Pfizer bought for a ton of money, that BHVN can use to develop other drugs. No earnings, no dividend.
I believe that whenever they report good news from a phase I, II or III trial, the stock will bounce a little.
Their weight-loss drug (early days), would be superior to Ozempic and the other drug because it will maintain muscle mass.
This company's research and development is extremely exciting, imo. I am jazzed!
https://finance.yahoo.com/news/biohaven-highlights-progress-across-innovative-123000745.html

[researcher59]

HALO +1.30 to 37.30 after posting solid Q4 numbers and reiterating strong growth for 2024 -

briefing -

Halozyme Therapeutics beats by $0.05, reports revs in-line; guides FY24 EPS above consensus, revs in-line; announces buyback (36.00 -0.10) :
Reports Q4 (Dec) earnings of $0.82 per share, excluding non-recurring items, $0.05 better than the FactSet Consensus of $0.77; revenues rose 26.7% year/year to $230.04 mln vs the $231 mln FactSet Consensus.
Co issues guidance for FY24, sees EPS of $3.55 to $3.90, excluding non-recurring items, vs. $3.34 FactSet Consensus; sees FY24 revs of $915 mln to $985 mln vs. $961.10 mln FactSet Consensus.
Board approved new $750 mln buyback.